{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"data_sharing_plan":["IPD Sharing (as of January 2016): No"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2179782"],"location":["France"],"study_start_month":["2"],"keyword":["Regorafenib, cohort, metastatic colorectal cancer"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting","description":"This is a largest cohort study aimed to estimate the overall survival of patients been treated with regorafenib for metastatic colorectal cancer (mCRC) within the frame of a french compassionate program.","dates":{"creation":"2014-02-15"},"accession":"2179782","cross_references":{"ClinicalTrials___gov":["NCT02310477"]}}